6RC.F ReproCELL Incorporated

Healthcare Biotechnology Frankfurt Exchange
0.5550 EUR
Close of Nov 12, 2026
0.4420 0.9550
Market cap
EUR 54.4M
P/E
-
P/B
1.02x
ROE
-6.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 6RC.F undervalued?

Graham number

The Graham number of ReproCELL Incorporated cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ReproCELL Incorporated fundamental analysis

No fundamental analysis for ReproCELL Incorporated yet.

ReproCELL Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ReproCELL Incorporated

ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells …

Full company profile